PUBLISHER: Orion Market Research | PRODUCT CODE: 1433295
PUBLISHER: Orion Market Research | PRODUCT CODE: 1433295
Global GMP Testing Service Market Size, Share & Trends Analysis Report by Technology (Single Stage and Double Stage), by Absorber Type (Lithium Bromide and Ammonia), by Power Source (Direct Fired, Indirect Fired, and Water Driven), and by Application (Chemicals, Food & Beverages, Power, Paper & Pulp, power & energy and Others), Forecast Period (2023-2030)
The global GMP testing service market is anticipated to grow at a CAGR of 6.7 % during the forecast period (2023-2030). The market's growth is attributed to growing healthcare preventive maintenance. GMP programs are a type of preventive healthcare that focuses on the early detection of growth problems in children. The requirement for GMP testing stems from the priority of ensuring the health and well-being of the next generation. According to the National Institute of Health, in May 2023, World Health Organization (WHO), an estimated 149 million children below the age of five years are affected by stunted growth and approximately 45.4 million children experience wasting. If left unaddressed, childhood malnutrition can lead to adverse effects on physical and intellectual development, an increased risk of diseases, reduced physical strength and work productivity, unemployment, and a higher risk of poverty that can extend to future generations. To tackle this issue, the United Nations Children's Fund (WHO) recommends the growth monitoring and promotion (GMP) program.
Furthermore, Growth monitoring and promotion (GMP) involves regularly tracking a child's weight and height, and taking actions to address any identified health issues. It has been implemented since the 1980s with the aims of identifying health and nutritional problems in children; promoting breastfeeding and appropriate complementary feeding; and increasing the utilization of child health services.
The global GMP testing service market is segmented on the service type, service provider, and end-user. Based on the service type, the market is sub-segmented into packaging and shelf-life testing,
product validation testing, bioanalytical services, and others. Based on the service provider, the market is sub-segmented into in-house testing facilities, and outsourced facility. Further, on the basis of end-user, the market is sub-segmented into pharmaceutical and biopharmaceutical companies, medical device companies, and others. The product validation testing subcategory is expected to capture a significant portion of the market share within the service type segment. This is attributed to the rise in demand for higher-quality and safe administration of service.
Among the end-user, the pharmaceutical and biopharmaceutical companies sub-segment is expected to hold a considerable share of the global GMP Testing Service market. The segmental growth is attributed to the growing integration of pharmacies. Medication management and administration are increasingly being handled by pharmacies and hospitals. On-site 3D printing can help healthcare facilities offer a more extensive and customized variety of therapies by streamlining the creation of personalized pharmaceuticals. For instance, in October 2023, CurifyLabs has launched GMP Pharma Inks for On-Site 3D Printing of Personalized medicines in pharmacies and hospitals. The pharmaceutical industry is recognizing the value in considering individual variation when prescribing medications, such as differences in genetics, age, gender, allergies, and disabilities.
The global GMP testing service market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of significant biopharmaceutical and pharmaceutical corporations in the countries such as the US. Furthermore, the increased frequency of substantial pharmaceutical businesses and their research and development operations drives the region's demand for GMP testing.
Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising concerns regarding public health. Poor-quality pharmaceuticals can impair public health by causing treatment failure, increasing drug resistance, and patient injury. This apprehension is a major motivator for the adoption of GMP standards and testing services. According to the BMC, in April 2022, World Health Organization (WHO), a significant portion of medicines available in low-income countries (LICs) and in Asia have been confirmed to be of poor quality. Up to 13.7% of medicines available in Asia have been reported to be of poor quality, and in more than one-third of countries, drug regulatory systems are either absent or lack stringent protocols. This poses a challenge to global health, as poor quality or substandard medicines can impede effective treatment, increase antimicrobial resistance, and create a socioeconomic burden.
Furthermore, the Afghan pharmaceutical sector is one of the least developed globally, with domestic manufacturers only meeting 5% of total pharmaceutical demand. The remaining 95% is imported from countries including Pakistan, China, India, Iran, United Arab Emirates (UAE), and Turkey. WHO has developed Good Manufacturing Guideline (GMP) standards to ensure consistent production of quality products. It is estimated that about one billion dollars of pharmaceuticals are smuggled into Afghanistan annually.
The major companies serving the GMP testing service market include includes Labcorp, Merck KGaA, Microchem Laboratories, North American Science Associates, LLC, Pace Analytical Services, LLC and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2022,GenScript USA Inc. launched the availability of new GMP-grade GenExact single-stranded DNA (ssDNA) and GenWand closed-end linear double-stranded DNA (dsDNA) services. The services provided enable next-generation gene and cell therapy R&D programs to proceed faster and more efficiently to IND filing and clinical trials.